Hrt Financial LP Eagle Pharmaceuticals, Inc. Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$17.74 - $31.87 $99,645 - $179,013	-5,617 Reduced 12.54%	39,166 $761,000
Q1 2023 May 12, 2023	SELL	$25.06 - $34.09 $407,876 - $554,848	-16,276 Reduced 26.66%	44,783 $1.27 Million
Q4 2022 Feb 10, 2023	BUY	$24.98 - $39.77 $1.53 Million - $2.43 Million	61,059 New	61,059 $1.78 Million
Q2 2022 Aug 12, 2022	BUY	$41.26 - $51.35 $10,851 - $13,505	263 Added 1.74%	15,389 $683,000
Q1 2022 May 16, 2022	SELL	$44.58 - $52.6 $195,572 - $230,756	-4,387 Reduced 22.48%	15,126 $748,000
Q4 2021 Feb 14, 2022	BUY	$45.82 - $56.9 $491,282 - $610,081	10,722 Added 121.97%	19,513 $993,000
Q3 2021 Nov 15, 2021	BUY	$43.79 - $55.78 $384,957 - $490,361	8,791 New	8,791 $490,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.